# Gujarat Themis Biosyn (NSE: GUJTHEM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/GUJTHEM · Pivot · prices to 22 Oct 2026

Gujarat Themis Biosyn (NSE: GUJTHEM) closed at ₹348.50 on 22 Oct 2026, down 0.06% on the day. With a market capitalisation of ₹3,797 Cr, it ranks 886th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 81.4× trailing earnings, against a return on equity of 19.6% in FY25. Over the past year the share price has fallen 16.0%. Its 52-week range is ₹225.05 (30 Mar 2026) to ₹479.00 (27 Oct 2025); the last close is 27.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹44 Cr (+17.2% year on year) and net profit ₹11 Cr (−9.3%), on a standalone basis. Promoters held 70.86% of the company as of 30 Jun 2026; 68.49% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹348.50 |
| Market cap | ₹3,797 Cr |
| P/E (trailing) | 81.4 |
| ROE | 19.6% (FY25) |
| ROCE | 23.5% (FY25) |
| Debt to equity | 0.12 |
| 52-week high | ₹479.00 (27 Oct 2025) |
| 52-week low | ₹225.05 (30 Mar 2026) |
| 1-year return | −16.0% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹44 Cr | +17.2% | ₹11 Cr | −9.3% | ₹1.00 |
| Q3 FY26 | ₹43 Cr | +9.7% | ₹12 Cr | −3.9% | ₹1.14 |
| Q2 FY26 | ₹42 Cr | +22.0% | ₹14 Cr | +34.9% | ₹1.31 |
| Q1 FY26 | ₹36 Cr | −7.6% | ₹9 Cr | −31.6% | ₹0.83 |
| Q4 FY25 | ₹38 Cr | −10.2% | ₹12 Cr | −24.5% | ₹1.10 |
| Q3 FY25 | ₹40 Cr | +1.7% | ₹13 Cr | −0.3% | ₹1.19 |
| Q2 FY25 | ₹35 Cr | −12.4% | ₹11 Cr | −15.7% | ₹0.97 |
| Q1 FY25 | ₹39 Cr | −21.7% | ₹13 Cr | −25.3% | ₹1.82 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹151 Cr | ₹49 Cr |
| FY24 | ₹170 Cr | ₹59 Cr |
| FY23 | ₹149 Cr | ₹58 Cr |
| FY22 | ₹115 Cr | ₹44 Cr |
| FY21 | ₹91 Cr | ₹30 Cr |
| FY20 | ₹85 Cr | ₹24 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 70.86%
- Foreign institutions: 1.77%
- Domestic institutions: 1.18%
- Non-institutions: 26.19%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Jeena Sikho Lifecare](https://app.pivotnow.in/stock/JSLL) | ₹348.50 | ₹4,332 Cr | 19.6 | — |
| [Novartis India](https://app.pivotnow.in/stock/NOVARTIND) | ₹1,686.90 | ₹4,165 Cr | 44.7 | — |
| [SMS Pharmaceuticals](https://app.pivotnow.in/stock/SMSPHARMA) | ₹427.80 | ₹4,006 Cr | 38.4 | — |
| [Gufic Biosciences](https://app.pivotnow.in/stock/GUFICBIO) | ₹390.20 | ₹3,913 Cr | 61 | — |
| [Aarti Drugs](https://app.pivotnow.in/stock/AARTIDRUGS) | ₹380.10 | ₹3,469 Cr | 17.8 | — |
| [Unichem Laboratories](https://app.pivotnow.in/stock/UNICHEMLAB) | ₹483.00 | ₹3,401 Cr | 13.5 | — |

## Questions and answers

### What is the share price of Gujarat Themis Biosyn today?

Gujarat Themis Biosyn (NSE: GUJTHEM) last closed at ₹348.50 on 22 Oct 2026. Its 52-week high is ₹479.00 and its 52-week low is ₹225.05.

### What is the market cap of Gujarat Themis Biosyn?

Gujarat Themis Biosyn's market capitalisation is ₹3,797 Cr (₹3,797 Cr) at the 22 Oct 2026 close, ranking 886th among the NSE companies Pivot tracks.

### What is the P/E ratio of Gujarat Themis Biosyn?

Gujarat Themis Biosyn trades at a trailing P/E of 81.4. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 38.4.

### What is the ROE and ROCE of Gujarat Themis Biosyn?

Return on equity was 19.6% in FY25 and return on capital employed was 23.5% in FY25 (standalone figures).

### Is Gujarat Themis Biosyn a debt-free company?

No. Gujarat Themis Biosyn's debt-to-equity ratio was 0.12 in FY25, with total debt of ₹30 Cr.

### What were Gujarat Themis Biosyn's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Gujarat Themis Biosyn reported revenue of ₹44 Cr, +17.2% year on year, and net profit of ₹11 Cr, −9.3% year on year.

### How has Gujarat Themis Biosyn stock performed over the last year?

Gujarat Themis Biosyn's share price has fallen 16.0% over the past year, −0.5% over three months and −15.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Gujarat Themis Biosyn?

As of 30 Jun 2026: promoters 70.86%, foreign institutions 1.77%, domestic institutions 1.18%, non-institutions 26.19%. 68.49% of promoter shares were pledged.

### Who are Gujarat Themis Biosyn's competitors?

The listed Pharma & Healthcare companies closest to Gujarat Themis Biosyn by market cap are Jeena Sikho Lifecare, Novartis India, SMS Pharmaceuticals, Gufic Biosciences, Aarti Drugs and Unichem Laboratories.

### Is Gujarat Themis Biosyn a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Gujarat Themis Biosyn's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GUJTHEM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.